NCT00337181 is a clinical trial in HIV-1, sponsored by U.S. Army Medical Research and Development Command.

Who is sponsoring NCT00337181?

NCT00337181 is sponsored by U.S. Army Medical Research and Development Command.

Is NCT00337181 still recruiting?

NCT00337181 is currently completed. Last updated 21 August 2018.

Are results published for NCT00337181?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-08-21 · How we verify

NCT00337181

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Become HIV-1 Infected During Participation in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX® B/E.

Completed Results posted Last updated 21 August 2018

What this trial tests

trial in HIV-1 in 114 participants. Completed in 1 June 2011.

Timeline

1 May 2006

Primary endpoint
1 March 2011

1 June 2011

Quick facts

Lead sponsor	U.S. Army Medical Research and Development Command
Status	Completed
Study type	OBSERVATIONAL
Enrollment	114
Start date	1 May 2006
Primary completion	1 March 2011
Estimated completion	1 June 2011
Sites	1 location across Thailand

Conditions studied

HIV-1 — all drugs for HIV-1 →

Sponsor

U.S. Army Medical Research and Development Command

Who can join

Adults 18 to 31, any sex, with HIV-1. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants Reaching Clinical Long Term Component Endpoints
Time frame: 66 months
Evaluate the vaccine effect on clinical long term endpoints: CD4 is for CD4\<350 endpoint; ART is for initiation of highly-active antiretroviral therapy (HAART) endpoint; ADI is for AIDS-defining illness endpoint; A combination of multiple endpoints is listed in order of occurrences of the endpoints

Sponsor's own description

This protocol will study the clinical course of HIV-infection among volunteers who have received either a placebo injection or the experimental vaccine combination of ALVAC-HIV and AIDSVAX B/E prior to HIV-1 infection in reference to study NCT00223080 RV144. The study will assess whether those who received the experimental vaccine combination have a slower progression of HIV disease compared to those who received the placebo injection.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

RV144 HIV-1 vaccination impacts post-infection antibody responses.
Mdluli T, Jian N, Slike B, Paquin-Proulx D, et al · · 2020 · cited 28× · PMID 33290394 · DOI 10.1371/journal.ppat.1009101
Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities.
Timofeeva A, Sedykh S, Nevinsky G. · · 2022 · cited 12× · PMID 35335016 · DOI 10.3390/vaccines10030384
HIV-1 infections with multiple founders associate with the development of neutralization breadth.
Lewitus E, Townsley SM, Li Y, Donofrio GC, et al · · 2022 · cited 8× · PMID 35303045 · DOI 10.1371/journal.ppat.1010369
Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection.
Siracusano G, Lopalco L. · · 2021 · cited 1× · PMID 35011639 · DOI 10.3390/cells11010077
Recent Advances in Nanoparticle-Based Antiretroviral Drug Delivery Systems for HIV Treatment and Prevention: A Comprehensive Review.
Das G, Shin HS, Patra JK. · · 2025 · PMID 41287764 · DOI 10.2147/ijn.s540578

Verify or expand the search:

Other recruiting trials for HIV-1

Currently open trials in the same condition.

NCT06517693 — Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1 · Phase 1 · recruiting
NCT06252402 — CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS · EARLY_PHASE1 · recruiting
NCT05612178 — A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs · Phase 1 · active not recruiting
NCT00980538 — TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants · Phase 3 · active not recruiting

Other U.S. Army Medical Research and Development Command trials

Trials by the same sponsor.

NCT05423418 — Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults · Phase 1 · completed
NCT05348993 — Single or Repeat Dose of G03-52-01 in Adult Subjects · Phase 2 · completed
NCT04658667 — HIV Vaccine in HIV-uninfected Adults · Phase 1 · completed
NCT04333459 — Safety and Immunogenicity of a Hantaan Virus DNA Vaccine and a Puumala Virus DNA Vaccine, For The Prevention of Hemorrha · Phase 2 · unknown
NCT03867162 — FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4) · Phase 2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00337181 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by U.S. Army Medical Research and Development Command
Last refreshed: 21 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00337181.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing